Therapeutic Asset Ratings

141 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Hydrochlorothiazide Stroke	Northern California Institute of Research and Education	P4	B (63)
carbidopa Stroke	University Hospital, Basel, Switzerland	P4	B (62)
Folic Acid Stroke	Beijing Tiantan Hospital	P4	B (62)
DEXKETOPROFEN Stroke	Region Örebro County	P3	B (62)
PROPRANOLOL Stroke	Beijing Tiantan Hospital	P3	B (62)
Cipralex Stroke	Johns Hopkins University	P4	B (61)
Keppra Stroke	Shanghai East Hospital	P4	B (61)
NEPENTHE Stroke	Region Örebro County	P3	B (61)
mlc1501 Stroke	Moleac Pte Ltd.	P2/3	B (61)
AMLODIPINE Stroke	Beijing Tiantan Hospital	P4	B (60)
CITALOPRAM Stroke	Chih-Wei Tang	P4	B (60)
FILGRASTIM Stroke	Vanderbilt University Medical Center	P4	B (60)
Semaglutide Stroke	University of Washington	P4	B (60)
VALSARTAN Stroke	Hospital Moinhos de Vento	P4	B (60)
Oxygen Stroke	Capital Medical University	P4	B (59)
Tizanidine Stroke	Northwestern University	P3	B (59)
CANDESARTAN Stroke	Beijing Tiantan Hospital	P4	B (58)
Ezetimibe Stroke	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	B (58)
Micardis® Stroke	Spaulding Rehabilitation Hospital	P4	B (58)
COLCHICINUM Stroke	Population Health Research Institute	P3	B (58)
Methylphenidate Stroke	VA Office of Research and Development	P4	B (57)
Aptoll Stroke	aptaTargets S.L.	P1/2	B (57)
3-N-BUTYLPHTHALIDE Stroke	Qianfoshan Hospital	P4	B (56)
BETAMETHASONE Stroke	Abant Izzet Baysal University	P4	B (56)
Cyclopofol Stroke	RenJi Hospital	P4	B (56)

Showing 26 to 50 of 141 assets